-
Mashup Score: 30
Researchers identify novel target for high-risk multiple myeloma
Source: www.mdanderson.orgCategories: General Medicine NewsTweet
-
Mashup Score: 32
Targeting cells that form blood vessels in glioblastoma could improve treatment
Source: www.mdanderson.orgCategories: General Medicine NewsTweet-
MD Anderson research findings suggest that targeting interactions between some cells around the blood vessels could help make glioblastoma more vulnerable to treatment. Read more: https://t.co/bBvhJ0Onme #EndCancer
-
-
Mashup Score: 3250 Most Influential Clinical Executives - 2025 - 3 day(s) ago
Modern Healthcare’s 50 Most Influential Clinical Executives awards recognize leaders with medical backgrounds in the industry.
Source: www.modernhealthcare.comCategories: General Medicine NewsTweet-
Congratulations to our Dr. Peter Pisters on being named one of Modern Healthcare's 50 Most Influential Clinical Executives for 2025. See the full list: https://t.co/206l0lIYxH @PPisters @modrnhealthcr #EndCancer https://t.co/xbjgZ0f4Tt
-
-
Mashup Score: 34What causes chemobrain? New insights - 6 day(s) ago
Many patients undergoing chemotherapy experience chemobrain, but what causes it? Researchers Jeffery Wefel, Ph.D., and Theresa Guise, M.D. describe new research into the role of “leaky” calcium channels in causing chemobrain, and what the implications for treatment could be.
Source: www.mdanderson.orgCategories: General Medicine NewsTweet-
Many oncologists hear from their patients undergoing chemotherapy that they're experiencing "chemobrain". What the latest research says about this common side effect and its possible causes: https://t.co/XC6KIfFTt9 #EndCancer
-
-
Mashup Score: 14
Real-world study found self-collection tests were effective at increasing cervical cancer screening participation in underserved U.S. populations Mail-in self-collection tests for human papillomavirus (HPV) more than doubled cervical cancer screening participation among never- and under-screened U.S. women, according to a first-of-its-kind study from researchers at The University of Texas MD Anderson Cancer Center. In the real-world, randomized, PRETIS study, published today in JAMA Internal Medicine,
Source: www.mdanderson.orgCategories: General Medicine NewsTweet-
Results published today from a real-world, randomized, PRETIS study, found self-collection HPV tests were effective at increasing cervical cancer screening participation. How this could reduce the burden of cervical cancer in the U.S.: https://t.co/3CuIMlDyWP #EndCancer
-
-
Mashup Score: 10Cancer Pain Management Symposium: Best Practices and Breakthroughs - MDA - Continuing Education (CE) - 7 day(s) ago
MDA, Cancer Pain Management Symposium: Best Practices and Breakthroughs, 11/1/2025 8:00:00 AM – 11/1/2025 3:35:00 PM, This activity will advance the understanding and management of cancer-related pain through the dissemination of the latest clinical research, emerging therapies, and evidence-based best practices globally. The goal is to bring together healthcare professionals, researchers, and thought leaders around the world to foster collaboration, innovation, and education. By focusing on personalized, multidisciplinary and interdisciplinary approaches to pain management, we aim to improve the quality of life for cancer patients and provide professionals with the tools to offer compassionate, effective care that addresses both the physical and emotional aspects of cancer pain.
Source: mdanderson.cloud-cme.comCategories: General Medicine NewsTweet-
Registration is now open for the Cancer Pain Management Symposium, a global event focused on advancing cancer pain care through new research findings, emerging therapies, and collaborative and compassionate approaches. Register here: https://t.co/anVK52HAJf #EndCancer https://t.co/snYKHEeQ6l
-
-
Mashup Score: 38
Researchers from The University of Texas MD Anderson Cancer Center will present research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These oral presentations address multiple tumor types and highlight key studies in immunotherapy, targeted therapy, and treatment strategies for aggressive and rare cancers.
Source: www.mdanderson.orgCategories: General Medicine NewsTweet-
Our researchers will present new, groundbreaking data at this year’s @ASCO Annual Meeting, including innovations in immunotherapy, targeted therapies and rare cancers. Read more: https://t.co/TQtveXeOiO #ASCO25 #EndCancer
-
-
Mashup Score: 38
Researchers from The University of Texas MD Anderson Cancer Center will present research at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These oral presentations address multiple tumor types and highlight key studies in immunotherapy, targeted therapy, and treatment strategies for aggressive and rare cancers.
Source: www.mdanderson.orgCategories: General Medicine NewsTweet-
Our researchers will present new, groundbreaking data at this year’s @ASCO Annual Meeting, including innovations in immunotherapy, targeted therapies and rare cancers. Read more: https://t.co/TQtveXeOiO #ASCO25 #EndCancer
-
-
Mashup Score: 32ASCO: New antibody-drug conjugate shows promising safety and response rates for patients with rare blood cancer - 10 day(s) ago
The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase I/II study led by researchers from The University of Texas MD Anderson Cancer Center.
Source: www.mdanderson.orgCategories: General Medicine News, Onc News and JournalsTweet-
New data from the CADENZA study shows pivekimab sunirine (PVEK) led to a 70% CR + CRc rate in frontline BPDCN with a manageable safety profile. Presented by Dr. Naveen Pemmarju at #ASCO25. #EndCancer https://t.co/mu9oBJbu2P @doctorpemm https://t.co/LwezghpUgJ
-
-
Mashup Score: 0Institute for Data Science in Oncology - 11 day(s) ago
MD Anderson’s Institute for Data Science in Oncology (IDSO) will harness the power of data and bring data science to every decision we make – accelerating the pace to end cancer and improve the lives of cancer patients and their families.
Source: www.mdanderson.orgCategories: General Medicine NewsTweet-
Meet Caroline Chung and Timothy Heffernan at booth 10059 on Monday, June 2 at 9 a.m. to learn how AI is accelerating drug discovery and transforming cancer treatment. Read more about our Institute for Data Science in Oncology: https://t.co/hZoXxWWpuU #EndCancer (2/7) @ca_chung https://t.co/ouViaGvCzq
-
Findings from new MD Anderson research suggest that CLPP, a protein in mitochondria, plays a key role in aggressive multiple myeloma, highlighting its potential as a therapeutic target. Learn more: https://t.co/L2IDZhmW7O #EndCancer